Marsha J Treadwell

List of Publications by Year
in descending order

77	1,990	304701	276858
papers	citations	22 h-index	41 g-index

81	81	81	2234
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. American Journal of Hematology, 2022, 97, 603-612.	4.1	25
2	Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE, 2022, 17, e0265342.	2.5	13
3	An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model. Quality of Life Research, 2022, 31, 2681-2694.	3.1	1
4	Social and Psychological Factors Associated With Health Care Transition for Young Adults Living With Sickle Cell Disease. Journal of Transcultural Nursing, 2021, 32, 21-29.	1.3	9
5	Electronic Health Recordâ€“Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study. JMIR Research Protocols, 2021, 10, e24818.	1.0	6
6	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
7	Patientâ€reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. American Journal of Hematology, 2021, 96, 1396-1406.	4.1	15
8	Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS ONE, 2021, 16, e0258638.	2.5	13
9	Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open, 2021, 11, e050880.	1.9	18
10	Improving Completion Rates of Transcranial Doppler Ultrasounds in Children with Sickle Cell Disease Using Quality Improvement Efforts: In-Clinic Vs. Population-Based Assessments. Blood, 2021, 138, 1886-1886.	1.4	0
11	Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematology,the, 2020, 7, e329-e341.	4.6	22
12	Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. Hematology, 2020, 25, 229-240.	1.5	3
13	Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Advances, 2020, 4, 4463-4473.	5.2	23
14	A National Measurement Framework to Assess and Improve Sickle Cell Care in 4 US Regions. Public Health Reports, 2020, 135, 442-451.	2.5	1
15	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	5.2	57
16	Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings. BMC Proceedings, 2020, 14, 21.	1.6	5
17	Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care. JAMA Network Open, 2020, 3, e206016.	5.9	30
18	Patientâ€reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. American Journal of Hematology, 2020, 95, 1066-1074.	4.1	24

#	Article	IF	Citations
19	Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28152.	1.5	15
20	Pediatric sickle cell disease. , 2020, , 185-206.		0
21	Understanding sickle cell disease: impact of surveillance and gaps in knowledge. Blood Advances, 2020, 4, 496-498.	5.2	4
22	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Research Protocols, 2020, 9, e16319.	1.0	19
23	Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. Blood, 2020, 136, 33-33.	1.4	1
24	Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry. Blood, 2020, 136, 3-3.	1.4	0
25	Sex Based Differences in Sickle Cell Disease. Blood, 2020, 136, 37-37.	1.4	0
26	Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2019, 41, 56-63.	0.6	11
27	Exploring the Role of Shared Decision Making in the Consent Process for Pediatric Genomics Research in Cameroon, Tanzania, and Ghana. AJOB Empirical Bioethics, 2019, 10, 182-189.	1.6	8
28	Establishing a Multi-Country Sickle Cell Disease Registry in Africa: Ethical Considerations. Frontiers in Genetics, 2019, 10, 943.	2.3	14
29	Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27525.	1.5	43
30	Pediatric residentsâ€™ perceived barriers to opioid use in sickle cell disease pain management. Pediatric Blood and Cancer, 2019, 66, e27535.	1.5	16
31	Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology, 2019, 24, 189-198.	1.5	42
32	Relation Between Religious Perspectives and Views on Sickle Cell Disease Research and Associated Public Health Interventions in Ghana. Journal of Genetic Counseling, 2019, 28, 102-118.	1.6	13
33	Lessons Learned from Building a Pediatric-to-Adult Sickle Cell Transition Program. Southern Medical Journal, 2019, 112, 190-197.	0.7	22
34	A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome. Blood, 2019, 134, 3470-3470.	1.4	0
35	Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. Hematology, 2018, 23, 683-691.	1.5	23
36	The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	4.1	52

#	Article	IF	Citations
37	Measurement of Sickle Cell Disease Symptoms from the Patient Perspective: Considerations for Clinical Trials. Blood, 2018, 132, 3571-3571.	1.4	1
38	Emergency department utilization by Californians with sickle cell disease, 2005â€“2014. Pediatric Blood and Cancer, 2017, 64, e26390.	1.5	40
39	Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An openâ€label, phase 2 study. American Journal of Medical Genetics, Part A, 2017, 173, 375-383.	1.2	24
40	Stakeholder Perspectives on Public Health Genomics Applications for Sickle Cell Disease: A Methodology for a Human Heredity and Health in Africa (H3Africa) Qualitative Research Study. OMICS A Journal of Integrative Biology, 2017, 21, 323-332.	2.0	7
41	Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMISÂ® to ASCQ-Meâ„¢. Health and Quality of Life Outcomes, 2017, 15, 117.	2.4	44
42	Impact of Elosulfase Alfa on Pain in Patients with Morquio A Syndrome over 52 Weeks. FIRE Forum for International Research in Education, 2017, 5, 232640981771885.	0.7	5
43	Self-efficacy and readiness for transition from pediatric to adult care in sickle cell disease. International Journal of Adolescent Medicine and Health, 2016, 28, 381-388.	1.3	33
44	Development of a sickle cell disease readiness for transition assessment. International Journal of Adolescent Medicine and Health, 2016, 28, 193-201.	1.3	23
45	Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A transâ€regional survey. American Journal of Hematology, 2016, 91, E461-2.	4.1	8
46	Quality of care in sickle cell disease. Medicine (United States), 2016, 95, e4528.	1.0	41
47	Community engagement to inform the development of a sickle cell counselor training and certification program in Ghana. Journal of Community Genetics, 2016, 7, 195-202.	1.2	16
48	Mortality Among Women with Sickle Cell Disease Admitted for Delivery, California 2004-2014. Blood, 2016, 128, 2332-2332.	1.4	0
49	Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, doubleâ€blind, pilot study. American Journal of Medical Genetics, Part A, 2015, 167, 2272-2281.	1.2	33
50	Teaching About Genetics and Sickle Cell Disease In Fifth Grade. Journal of the National Medical Association, 2015, 107, 4-10.	0.8	6
51	Using Formative Research to Develop a Counselor Training Program for Newborn Screening in Ghana. Journal of Genetic Counseling, 2015, 24, 267-277.	1.6	19
52	Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatric Blood and Cancer, 2014, 61, 2271-2276.	1.5	39
53	Adult Sickle Cell Quality-of-Life Measurement Information System (ASCQ-Me). Clinical Journal of Pain, 2014, 30, 902-914.	1.9	60
54	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361

#	Article	IF	Citations
55	Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks. Health and Quality of Life Outcomes, 2014, 12, 125.	2.4	73
56	A Quality Improvement Initiative to Improve Emergency Department Care for Pediatric Patients with Sickle Cell Disease. Journal of Clinical Outcomes Management, 2014, 21, 62-70.	1.7	7
57	A Biopsychosocial-Spiritual Model of Chronic Pain in Adults with Sickle Cell Disease. Pain Management Nursing, 2013, 14, 287-301.	0.9	33
58	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. Blood, 2012, 120, 2101-2101.	1.4	3
59	Autonomic Nervous System Reactivity. Nursing Research, 2011, 60, 197-207.	1.7	10
60	Transition from pediatric to adult care in sickle cell disease: Establishing evidenceâ€based practice and directions for research. American Journal of Hematology, 2011, 86, 116-120.	4.1	88
61	Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. Blood, 2011, 118, 337-337.	1.4	0
62	Chart Card: Feasibility of a Tool for Improving Emergency Department Care in Sickle Cell Disease. Journal of the National Medical Association, 2010, 102, 1017-1024.	0.8	7
63	Stress Reactivity as a Moderator of Family Stress, Physical and Mental Health, and Functional Impairment for Children With Sickle Cell Disease. Journal of Developmental and Behavioral Pediatrics, 2010, 31, 491-497.	1.1	19
64	Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings. Journal of Behavioral Medicine, 2008, 31, 506-516.	2.1	16
65	Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. Journal of the National Medical Association, 2006, 98, 704-10.	0.8	55
66	A Simple Model to Assess and Improve Adherence to Iron Chelation Therapy with Deferoxamine in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 486-491.	3.8	14
67	Autonomic reactivity and clinical severity in children with sickle cell disease. Clinical Autonomic Research, 2005, 15, 400-407.	2.5	60
68	Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatric Blood and Cancer, 2005, 44, 500-507.	1.5	48
69	Quality of Life (QOL) in Sickle Cell Disease (SCD).. Blood, 2005, 106, 1324-1324.	1.4	0
70	Barriers to Deferoxamine Adherence for Adults with Sickle Cell Disease.. Blood, 2004, 104, 3760-3760.	1.4	2
71	Assessing Compliance to Iron Chelation Therapy in Patients with Thalassemia.. Blood, 2004, 104, 3787-3787.	1.4	2
72	Using quality improvement strategies to enhance pediatric pain assessment. International Journal for Quality in Health Care, 2002, 14, 39-47.	1.8	95

#	ARTICLE	IF	CITATIONS
73	Assessment of Sickle Cell Pain in Children and Young Adults Using the Adolescent Pediatric Pain Tool. Journal of Pain and Symptom Management, 2002, 23, 114-120.	1.2	55
74	Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Seminars in Hematology, 2001, 38, 77-84.	3.4	30
75	Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Seminars in Hematology, 2001, 38, 77-84.	3.4	25
76	Practice Guidelines for the Assessment of Children With Sickle Cell Pain. Journal for Specialists in Pediatric Nursing, 1999, 4, 61-73.	1.1	19
77	Transitioning Adolescents With Sickle Cell Disease From Pediatric to Adult Care: Results From a New Survey of Health Care Professionals. Journal of Pediatric Hematology/Oncology, 0, Publish Ahead of Print, .	0.6	0